atrial fibrillation - search results
If you're not happy with the results, please do another search
Low BMI associated with cardiac tamponade during catheter ablation for atrial fibrillation
A recent analysis of a large nationwide database of patients with atrial fibrillation (AF) who underwent ablation has reported an independent association between being...
Analysis of NIS database shows racial disparities in atrial fibrillation outcomes in heart failure
Using data from a large and “nationally representative” sample of the US population, a recent study is the first—the authors posit—to demonstrate racial differences...
Brainomix technology integrated into new UK atrial fibrillation study
Brainomix has announced its involvement in a new study sponsored by the University of Liverpool (Liverpool, UK) focused on post-stroke atrial fibrillation (AF). Sites...
Basketballer Kareem Abdul-Jabbar joins campaign to raise awareness of atrial fibrillation
Kareem Abdul-Jabbar is working with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AF) and its symptoms as part of the...
Continuous monitoring detects atrial fibrillation in 20% of atherosclerotic stroke survivors
In a study presented yesterday at the International Stroke Conference (ISC; 8–10 February, Dallas, USA), irregular heart rhythms were detected in roughly one in...
Atrial fibrillation does not modify treatment effect of bridging thrombolysis, study finds
An international study conducted by Leonard Yeo (National University Hospital, Singapore) and colleagues has found that the presence of atrial fibrillation does not modify...
Catheter ablation shown to reduce mortality and hospitalisation in patients with atrial fibrillation and...
An analysis of randomised controlled trials (RCTs) has found catheter ablation reduces mortality and heart failure hospitalisations in patients with atrial fibrillation (AF) and...
Same-day discharge for catheter ablation of atrial fibrillation deemed safe and feasible
A recent systematic review and meta-analysis, published in the Journal of Interventional Cardiac Electrophysiology, has deemed same-day discharge following catheter ablation of atrial fibrillation...
Alternative timing method for direct oral anticoagulants following ischaemic stroke with atrial fibrillation deemed...
A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...
AcQForce PFA-CE study begins for focal PFA therapy to treat atrial fibrillation
Acutus Medical has announced the initiation of AcQForce PFA-CE, a clinical study that will evaluate the safety and performance of the company’s focal force...
Pulsed field ablation poised to revolutionise the treatment of atrial fibrillation
The advent of pulsed field ablation (PFA) will revolutionise the treatment of atrial fibrillation (AF), Tom de Potter (Aalst, Belgium) tells Cardiac Rhythm News,...
Patients with both atrial fibrillation and diabetes less likely to notice an irregular heartbeat
Adults with type 1 or type 2 diabetes and atrial fibrillation (AF) are less likely to notice irregular heartbeat symptoms, more likely to have...
Exploring the potential of remote atrial fibrillation diagnosis through digital technology
The challenge of rapid detection and diagnosis of atrial fibrillation (AF) has been made even harder with the onset of the COVID-19 pandemic, and...
EHRA 2021: Efforts should be made to increase participation in atrial fibrillation screening
Further efforts should be made to increase participation in atrial fibrillation (AF) screening—particularly in elderly populations, where systematic screening for AF can help to...
AHA 2020: Higher level of fitness reduces atrial fibrillation risk
Higher fitness levels reduced the risk of developing atrial fibrillation (AF) by 30‒50% in a study of male, African American veterans, according to preliminary...
Machine learning approach could detect drivers of atrial fibrillation
Researchers have designed a new machine learning-based approach for detecting atrial fibrillation (AF) drivers, small patches of the heart muscle that are hypothesised to...
LIVE from SNIS: Bridging therapy independently predicts haemorrhagic complications in atrial fibrillation associated stroke
Exposure to bridging therapy independently predicts haemorrhagic complications—without improving functional outcomes—in patients with atrial fibrillation (AF) associated stroke. The findings from this retrospective, registry...
Atrial fibrillation deaths “declining”, study finds
A study by researchers from the Boston University School of Public Health (BUSPH, Boston, USA) shows a decline in deaths related to atrial fibrillation...
AF Symposium 2020: Cryoablation pulmonary vein isolation is safe and effective for persistent atrial...
Hugh Calkins (Johns Hopkins Medical Institutions, Baltimore, USA) told delegates attending the AF Symposium 2020 (23–25 January, Washington, DC, USA) that cryoablation with the...
Persistent atrial fibrillation—seeking the sources of the cardiac electrical field
Andrew Grace charts the evolution of non-contact mapping culminating in the current AcQMap system—the technology has advanced understanding of persistent atrial fibrillation (AF), providing...
Biosense Webster launches initiatives to tackle atrial fibrillation
Biosense Webster, a Division of Johnson & Johnson, has reaffirmed its commitment to tackling atrial fibrillation (AF) by launching two major initiatives to coincide...
President of Venice Arrhythmias discusses current challenges in atrial fibrillation management
Antonio Raviele (Venice, Italy), the president of Venice Arrhythmias 2019 (3–5 October; Venice, Italy), talks to BLearning Cardio about some of the current challenges in atrial fibrillation (AF)...
Individualised home-based education dramatically decreases atrial fibrillation-related hospitalisations and other cardiovascular admissions
Personalised education delivered in a home setting significantly reduces hospitalisations in patients with atrial fibrillation (AF). This was among the findings of the HELP-AF...
iRhythm and Verily to collaborate on health management solutions for atrial fibrillation patients
iRhythm Technologies has announced a collaboration with Verily to develop solutions aimed at improving the screening, diagnosis, and management of patients with atrial fibrillation...
Deep learning AI may identify atrial fibrillation from a normal rhythm ECG
An artificial intelligence (AI) model has been found to identify patients with intermittent atrial fibrillation even when performed during normal rhythm using a quick...
New technology improves atrial fibrillation detection after stroke
A new method of evaluating irregular heartbeats outperformed the approach that is currently used widely in stroke units to detect instances of atrial fibrillation.
The...
EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation
Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Medtronic) is associated with a reduction in subclinical atrial fibrillation in...
High power short duration ablation for atrial fibrillation: Safety and effectiveness
As part of a session on novel mapping and ablation technologies of atrial fibrillation (AF) at the recent AF Symposium in Boston, USA (24–26...
Mapping dynamic patterns during atrial fibrillation can produce higher success rates
In a late breaking session at the 2019 AF Symposium in Boston, USA (24–26 January), it was announced that a dipole density (DD) mapping...
More than 40% of patients with a history of atrial fibrillation attend the emergency...
Patients with a previous diagnosis of atrial fibrillation who were assessed as attending the emergency department inappropriately did so because of fear, or as...
Combining practical and scientific learning to meet educational needs at Europe’s largest atrial fibrillation...
Sabine Ernst and Mattias Duytschaever are both consultant cardiologists and scientific committee members of the practical and scientific faculty of the Atrial Fibrillation Symposium,...
Patients with atrial fibrillation who are frail or have cognitive impairment are less likely...
Malini Madhavan (Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA) and others reported the results of a study in American Heart Journal that found...
New financing to commercialise Globe system for treatment of atrial fibrillation
In a new financing round, Kardium has raised an undisclosed amount to fund commercial activities in Europe and Canada, and for clinical testing of the Globe...
Top 10 takeaways – the need to increase focus and awareness of atrial fibrillation
A new report from Biosense Webster sets out the scale and impact of atrial fibrillation (AF) across Europe and calls for greater awareness and...
New AHA treatment guidelines for use of blood thinners with atrial fibrillation
A newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs), is now recommended as the preferred alternative to warfarin for reducing the risk...
New option available for physicians treating patients with atrial fibrillation
Approval has been granted for Abbot’s TactiCath Contact Force Ablation Catheter, Sensor Enabled, which is helping more physicians integrate ablation with 3D mapping to...
The link between atrial fibrillation and obstructive sleep apnoea
Obstructive sleep apnoea and atrial fibrillation (AF) have presented many challenges, including identifying which patients need to be assessed for obstructive sleep apnoea and...
First patient treated in STELLAR US study evaluating next-generation balloon ablation catheter for atrial...
Biosense Webster has enrolled and treated the first patient in its STELLAR US investigational device exemption (IDE) study. The study will evaluate the safety...
AI-based solution to screen atrial fibrillation to improve stroke prevention
Maisense, a start-up company specialising in stroke prevention, has recently introduced an AI-based solution that can screen stroke through early detection of atrial fibrillation...
Capacity of the Apple Watch to determine atrial fibrillation examined in the largest study...
Researchers at Stanford University's School of Medicine have completed enrolment of a large-scale study using the Apple Watch to determine whether a wearable technology...
Atrial fibrillation related to PFO closure occurs early and is transient
A new meta-analysis of patients undergoing percutaneous closure of patent foramen ovale (PFO) after cryptogenic shock supports previous studies that indicate PFO closure is...
Adagio Medical treats first atrial fibrillation patients using new One Shot+ cryoablation catheter
Adagio Medical, the developer of the iCLAS technology—the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias—announces that the...
Patients with new-onset atrial fibrillation after TAVI have highest risk of complications
Amit N Vora (Duke University Medical Center/the Duke Clinical Research Institute, Durham, USA) and others report in in JACC: Cardiovascular Interventions that patients who...
Four out of 10 patients with atrial fibrillation have unknown brain damage
Four out of ten patients with atrial fibrillation but no history of stroke or transient ischaemic attack have previously unknown brain damage, according to...
CABANA trial provides important new data on clinical and quality of life effects of...
Catheter ablation for atrial fibrillation (AF) produced no significant improvement in death, disabling stroke, serious bleeding, or cardiac arrest but did reduce death or...
Obese people with atrial fibrillation can reduce or reverse the effects of the condition...
Published in the heart journal Europace, the researchers found that a 10% loss in weight along with management of associated risk factors, can reverse the...
Algorithm can accurately detect atrial fibrillation and differentiate from sinus rhythm
The algorithm (Kardiaband, AliveCor) for atrial fibrillation (AF) detection, when supported by physician review can accurately differentiate AF from sinus rhythm (SR). This technology...
More than US$28 million awarded for new atrial fibrillation research centres to improve patient...
The American Heart Association has announced research grants totalling more than US$28 million to the scientific teams that will create a new research network...
Zenicor selected as supplier to the world’s largest screening programme for atrial fibrillation
Zenicor Medical Systems AB has been selected as sole supplier for a screening programme in the UK for atrial fibrillation. The screening programme is...
Surgical treatment of atrial fibrillation results in higher complication rates when compared to catheter...
The total procedure-related complications after surgical minimally invasive pulmonary vein isolations (MIPI) were higher; this was mainly due to more major complications. During a...
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and...
Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 (Anticoagulation using the direct factor...
Left atrial function measures predict atrial fibrillation
The Copenhagen City Heart Study set out to investigate whether left atrial (LA) functional measures predict atrial fibrillation (AF) in the general population. They...
Atrial fibrillation detection with smartwatch or smartphone camera achieved >95% accuracy
The results of the WATCH AF trial, the world’s first international, prospective and double-blinded clinical trial (ClinicalTrials.gov ID: NCT02956343) evaluating the accuracy of a...
New real-world study finds long-term rivaroxaban use resulted in fewer strokes and systemic emboli...
Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy...
Study to evaluate novel high power, short duration modality for treatment of atrial fibrillation...
The first patient has been enrolled and treated in the QDOT AF study (Biosense Webster). The study will evaluate the delivery of high...
FDA approval of the next-generation HeartLight Excalibur balloon designed for the treatment of paroxysmal...
The US Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial...
Activation patterns at termination sites reveal stable rotation in human persistent atrial fibrillation
Local activation mapping at sites of termination of persistent atrial fibrillations (AF) shows repetitive patterns including rotational or focal activity reports a study in...
Catheter ablation for atrial fibrillation: Lessons and developments
It was a year of big results for catheter ablation, continuing the procedure’s steady rise in atrial fibrillation (AF) management. Mark O’Neill, consultant cardiologist...
Study shows positive results with cryoballoon for patients with persistent atrial fibrillation
One-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance Cryoballoon to isolate the pulmonary veins in patients with symptomatic...
Study finds the heart can terminate atrial fibrillation itself after local gene therapy
The heart is capable of terminating arrhythmias itself after local gene therapy, potentially avoiding the need for patients to undergo painful electric shocks, according...
Stroke prevention drugs may help reduce dementia risk for atrial fibrillation patients
Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online in EP Europace1, a...
Zio by iRhythm shown to improve detection of previously undiagnosed atrial fibrillation
iRhythm Technologies has announced primary results of the mHealth Screening to Prevent Strokes (mSToPS) study that evaluated detection of silent atrial fibrillation (AF) in...
New-onset atrial fibrillation after CABG significantly increases the risk of death and stroke in...
New data from the EXCEL trial, which found that percutaneous coronary intervention (PCI) was non-inferior to coronary artery bypass grafting (CABG) at three years...
African Americans with atrial fibrillation at significantly higher risk of stroke
African Americans with atrial fibrillation (AF) have a significantly higher risk of stroke than Caucasians with the condition, according to new research published in HeartRhythm by...
New data demonstrates >90% year 1 success rate for radiofrequency ablation in treating patients...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...
Biomarker predicts success of atrial fibrillation treatment
Written by Hannah Woolley, Cardiac Rhythm News Editor
Heart imaging has been successfully used to predict the benefit or futility of catheter ablation. The investigators...
Warfarin linked to lower rate of cancer, particularly for atrial fibrillation patients
A recent study by Gry Haaland (University of Bergen, Bergen, Norway) et al published in the Journal of the American Association of Medicine (JAMA):...
Acesion Pharma receives approval for Phase I study in atrial fibrillation
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announced it has received approval to...
Activation patterns at termination sites reveal stable rotation in human persistent atrial fibrillation
Local activation mapping at sites of termination of persistent atrial fibrillations (AF) shows repetitive patterns including rotational or focal activity reports a study in...
Results of CASTLE-AF trial published: catheter ablation better than conventional drug therapy for atrial...
The results of the CASTLE-AF study, published today in the New England Journal of Medicine, show that patients treated with radiofrequency catheter ablation rather than...
Cluster analysis reveals “considerable heterogeneity” of atrial fibrillation
A cluster analysis of the data from the ORBIT-AF observational registry study has been published by Taku Inohara (Duke University Medical Center, Durham, USA)...
Have you considered this sleeping burden of atrial fibrillation (AF)?
This video has been sponsored by LivaNova.
AF is a growing epidemic affecting 33.5 million people today.1 Up to 91% of AF patients have co-morbidities.2 Among...
Men develop atrial fibrillation earlier than women; extra weight a factor
A study published in the American Heart Association’s journal Circulation has found that men develop atrial fibrillation (AF) about a decade earlier than women on...
Catheter ablation lowers mortality in atrial fibrillation patients with heart failure
Catheter ablation of atrial fibrillation significantly reduces mortality and hospitalisation in atrial fibrillation patients with heart failure in comparison with conventional treatment, data from...
Smartphone apps launched for atrial fibrillation patients and their healthcare providers
Two novel smartphone and tablet applications (apps) for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The two apps will...
Significant differences among atrial fibrillation patients across Asia
The latest results from one of the largest, ongoing global disease registries in atrial fibrillation (AF)— GARFIELD-AF (global anticoagulant registry in the field-atrial fibrillation)...
ESC 2017: New subanalysis highlights benefits of edoxaban over warfarin in atrial fibrillation patients
New subanalysis data demonstrate edoxaban (Lixana, Daiichi Sankyo) provide comparable efficacy and greater safety compared to warfarin, across non-valvular atrial fibrillation patients with different...
ESC 2017: Atrial fibrillation associated with a high financial, economic, and human burden
The first health economics data from GARFIELD-AF (Global anticoagulant registry in the field–atrial fibrillation) was presented at the European Society of Cardiology (ESC) congress...
ESC 2017: Apixaban lowers risk of stroke in atrial fibrillation patients undergoing cardioversion
Data from the EMANATE trial, which was presented at a Hot Line session of the European Society of Cardiology (ESC) congress (26–30 August, Barcelona,...
ESC 2017: Case builds for dropping aspirin from triple therapy in atrial fibrillation patients...
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...
Long working hours associated with higher risk of atrial fibrillation
By Angela Gonzalez
People working 55 hours or more a week had an approximately 40% higher risk of atrial fibrillation compared with people working 35...
Europace 2017: Stroke history higher in asymptomatic versus symptomatic atrial fibrillation patients
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with symptoms, according to results from the GLORIA-AF registry...
Medtronic Reactive ATP therapy slows atrial fibrillation progression in real-world population
Medtronic has announced that its Reactive atrial-based antitachycardia pacing (ATP) therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices....
HRS 2017: True incidence of atrial fibrillation is underestimated
A substantial number of patients at risk for atrial fibrillation (AF) may remain undetected using conventional monitoring techniques, a late-breaking clinical trial session at...
Survey finds 79% of atrial fibrillation patients would say “yes” to self-monitoring
A new AF atrial fibrillation (AF) patient survey carried out by the AF Association has been launched. Results showed that 79% of patients surveyed—who...
Taller, heavier women have nearly threefold greater risk of atrial fibrillation
Women who are taller, heaver and have a greater body surface area have a nearly threefold greater risk of atrial fibrillation than smaller women,...
ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation ablation
Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...
ACC 2017: Anticoagulant treatment may be unnecessary for stroke prevention following ablation for atrial...
For patients with persistent atrial fibrillation or those who are at high risk for recurring atrial fibrillation, catheter ablation is recommended, followed most often...
AliveCor unveils first artificial intelligence-enabled platform for early atrial fibrillation detection
AliveCor has release the Kardia Pro, an industry-first artificial intelligence-enabled platform for doctors to monitor patients for the early detection of atrial fibrillation, in...
Superior vena cava does not seem to contribute to long-standing persistent atrial fibrillation
The arrhythmogenicity of the superior vena cava has been rarely detected in patients with long-standing persistent atrial fibrillation, according to study from China recently...
Case strengthens for opportunistic atrial fibrillation screening
By Angela Gonzalez
In the quest to reduce the number of atrial fibrillation (AF) related strokes, which account for a third of all ischaemic strokes,...
STS recommends surgical ablation as an “effective” treatment for atrial fibrillation
The Society of Thoracic Surgeons (STS) has issued new clinical guidelines that include major recommendations for the use of surgical ablation when treating atrial...
Moderate, habitual alcohol intake associated with atrial fibrillation
People who binge drink often experience an irregular heartbeat or a heart “flutter,” sometimes referred to as “holiday heart syndrome.” However, people who drink...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...
Patient enrolment complete in study assessing use of dabigatran atrial fibrillation patients undergoing PCI
Patient enrolment into the international Phase IIIb RE-DUAL PCI study is complete. The study is evaluating the safety and efficacy of dabigatran (Pradaxa, Boehringer...
Charity believes NHS programme will leave hundreds of atrial fibrillation patients at risk of...
Arrhythmia Alliance, the UK-based heart rhythm charity, is calling on NHS England to reconsider a programme that it says will mean the “hundreds” of...
Short episodes of atrial fibrillation may not increase risk of stroke
People with pacemakers or defibrillators who experience only short episodes of atrial fibrillation have a very low risk of stroke, suggesting that anticoagulants in...
World Heart Federation launches global Roadmap to tackle atrial fibrillation
With the aim to help prevent atrial fibrillation (AF) and to improve its management worldwide— particularly in low- and middle-income countries—the World Heart Federation...
First US commercial atrial fibrillation procedure with HeartLight system performed at Mount Sinai
CardioFocus has announced the first commercial US procedure using its HeartLight Endoscopic Ablation system for the treatment of patients with paroxysmal atrial fibrillation (AF)...
ESC 2016: “User-friendly” risk score may help to better identify atrial fibrillation patients at...
A new risk score, based on data from GARFIELD-AF (Global anticoagulation registry in the field), may be superior to the CHA2DS2-VASc score at predicting...
Daily alcohol consumption may lead to atrial fibrillation
Despite the common perception that moderate alcohol intake is good for the heart, new research suggests long-term alcohol consumption, even as little as one...
Atrial fibrillation linked to wider range of serious conditions than previously thought
Atrial fibrillation is associated with a wide range of serious events, including heart attacks, heart failure, chronic kidney disease, and sudden cardiac death, a...
ESC and EACTS launch first collaborative atrial fibrillation guidelines
The first European Society of Cardiology (ESC) Guidelines on Atrial Fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) have been...
Atrial fibrillation and heart failure: The ugly and the nasty
W: www.bk1.it/events
Daiichi Sankyo PREFER in AF registry suggests increased stroke risk among diabetic atrial fibrillation...
Daiichi Sankyo has announced data from new sub-analyses of the Prevention of thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) patient registry, which...
Medtronic EffectivCRT-during atrial fibrillation algorithm can improve therapy delivery
The Cardiac Resynchronization Therapy Efficacy Enhancement (CRTee) study has shown that the Medtronic EffectivCRT-during atrial fibrillation algorithm can improve therapy delivery in heart failure...
Thrombosis Research Institute to announce new real-world GARFIELD-AF registry insights in atrial fibrillation at...
New analyses from the Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) will be presented at the European Society of Cardiology (ESC) Congress (27‒31...
Educational supplement: LAA closure for stroke prophylaxis in atrial fibrillation
This educational supplement is only for readers in countries outside France, Japan and the USA
In this educational supplement, sponsored by Boston Scientific, Cardiac Rhythm News explores left...
Sudden cardiac death is the most common cause of death in atrial fibrillation patients,...
An analysis from the ENGAGE AF-TIMI 48 trial has found that sudden cardiac death was the single most common cause of death and accounted...
Insights into genetically-targeted prevention of atrial fibrillation in heart failure patients
The current need for new preventative therapies of atrial fibrillation in chronic heart failure patients—with fewer side effects than currently available treatment strategies—has led...
Performance and quality measures updated for patients with atrial fibrillation
The American College of Cardiology (ACC) and the American Heart Association (AHA) have released updated clinical performance and quality measures for treating adult patients with atrial...
Catheter ablation is superior to amiodarone in the treatment of patients with heart failure...
New research indicates that catheter ablation may achieve greater long-term freedom from atrial fibrillation, as well as a reduction in unplanned hospitalisation and mortality...
Yoga may help as a complementary treatment for paroxysmal atrial fibrillation
A randomised controlled study has found that yoga with light movements and deep breathing may lead to improved quality of life, as well as...
Routine ganglionic plexus ablation “should not be performed” in advanced atrial fibrillation patients
Results from the AFACT trial have shown no clinical benefits and significantly more complications associated with routine ganglionic plexus ablation for advanced atrial fibrillation patients. Data were presented at the 37th Heart Rhythm Society Scientific Sessions (HRS; 4-7 May, San Francisco, USA).
Medtronic’s Reveal LINQ detects atrial fibrillation at higher rate than previously recorded
Medtronic has announced one-year results from a real-world study of patients who had a cryptogenic stroke, or stroke of unknown cause.
HeartLight System gets FDA approval for atrial fibrillation treatment
CardioFocus has announced that it has received premarket approval from the US Food and Drug Administration (FDA) for its HeartLight Endoscopic Ablation System for the treatment of patients with paroxysmal atrial fibrillation.
Atrial fibrillation patients at highest stroke risk not prescribed necessary medication
Nearly half of all atrial fibrillation patients at the highest risk for stroke are not being prescribed blood thinners by their cardiologists, according to a new study.
Fluoroscopy times and radiation dose reduced in atrial fibrillation ablation with contact force-sensing technology
A real-world study has found that the SmartTouch (Biosense Webster) contact force-sensing catheter coupled with an Advanced Catheter Location feature during atrial fibrillation (AF) ablation reduced fluoroscopy times by 77%, radiation dose by 71% and procedural time by 19%.
First patient enrolled in AtriCure postoperative atrial fibrillation study
The first patient has been enrolled in the ATLAS (AtriClip Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures) clinical study.
Hybrid and surgical atrial fibrillation ablation: Opportunity, threat or both?
Despite major advances in techniques and technology over the past 15 years, the clinical outcomes for catheter ablation in non-paroxysmal atrial fibrillation patients remain...
Arca enrols 50th patient in GENETIC-AF atrial fibrillation prevention trial
This trial evaluates bucindolol hydrochloride (Gencaro) as a potential genetically-targeted treatment for the prevention of atrial fibrillation.
German public health body grant once-daily edoxaban indication for prevention of stroke in non-valvular...
The German Federal Joint Committee (Gemeinsamer Bundesausschuss-G-BA) has granted Daiichi Sankyo's edoxaban (Lixiana) an indication of a minor additional benefit.
New ultrasound-based system shows promise mapping atrial fibrillation
Initial findings have shown that a new ultrasound-based imaging system with continuous dipole density mapping provides real-time rapid global left atrial reconstruction and compares favourably to segmented computed tomography (CT).
First patient enrolled in international CEASE atrial fibrillation study
The first patient has been enrolled in the CEASE (combined endoscopic epicardial and percutaneous) atrial fibrillation (AF) clinical study, according to a press release from AtriCure.
B3 trial to evaluate benefits of unique rate response algorithm for atrial fibrillation patients...
This trial aims to determine if closed loop stimulation can delay the onset of atrial fibrillation and reduce the risk of stroke.
Medtronic receives CE mark for new single-chamber ICDs designed to detect atrial fibrillation
The Visia AF and Visia AF MRI SureScan are designed to detect and monitor new onset, asymptomatic and previously undiagnosed atrial fibrillation.
Pacemakers identify atrial fibrillation and enable initiation of stroke prevention
According to research presented at Acute Cardiovascular Care 2015, pacemaker checks are a good way to identify new cases of atrial fibrillation so that anticoagulation can be started to prevent strokes.
NICE recommends once-daily Lixiana (edoxaban) for preventing stroke and systemic embolism in non-valvular atrial...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism in patients suffering from atrial fibrillation.
Laguna Pharmaceuticals initiates phase 3 study of vanoxerine in atrial fibrillation and atrial flutter
The study, known as RESTORE SR, will enrol 600 subjects at trial sites in the USA and other countries and will evaluate vanoxerine at a 400mg dose.
CardioFocus’ HeartLight PMA for the treatment of atrial fibrillation filed and accepted for review...
The accepted PMA application includes safety and effectiveness data from the company's multicentre HeartLight pivotal clinical trial, a randomised, controlled study in which a total of 353 patients were treated at 19 US centres.
New real-world study reveals low bleeding rates with rivaroxaban in atrial fibrillation patients
Results from the real-world study XANTUS have shown low rates of major bleeding in patients with atrial fibrillation taking rivaroxaban (Xarelto, Bayer Healthcare) for stroke prevention. Data were consistent with findings from the pivotal phase III clinical trial, ROCKET-AF.
Secondhand smoke during pregnancy and early childhood linked to atrial fibrillation in adult life
A first-of-its-kind study indicates that gestational and early life secondhand smoke exposure may double one's chance of developing atrial fibrillation as an adult.
Second generation cryoballoon shows favourable outcomes treating persistent atrial fibrillation
The largest study to date exploring the mid-term efficacy of cryoablation with the second generation device has shown favourable outcomes in patients with persistent atrial fibrillation. At a median follow-up of 10 months, 67% of patients were in sinus rhythm.
WomenHeart launches first virtual support network for women living with atrial fibrillation and their...
The programme, which starts in September during Atrial Fibrillation Awareness Month, aims to reach women living with heart disease who do not otherwise have access to patient support services.
NICE recommends once-daily edoxaban for preventing stroke and systemic embolism in non-valvular atrial fibrillation...
NICE Final Appraisal Determination recommends that edoxaban is a cost-effective use of NHS resources.
Racial and gender disparities in care exist for patients newly-diagnosed with atrial fibrillation
New study published in HeartRhythm shows differences in the utilisation of atrial fibrillation therapies in a large nationwide population.
FDA approves trial to evaluate Lariat ligation of the left atrial appendage as a...
The randomised, controlled AMAZE trial, will evaluate the use of the Lariat device for the ligation of the left atrial appendage as an adjunctive treatment to ablation in patients with persistent or long-standing persistent atrial fibrillation.
One-year outcomes on stroke prevention in patients with newly-diagnosed atrial fibrillation to be presented...
Real-life data on stroke prevention from 17,200 patients will provide information on how patient risk profiles and quality of vitamin K antagonist control are associated with increased mortality and stroke in patients with newly diagnosed atrial fibrillation.
Intravenous vernakalant facilitates electrical cardioversion in patients with cardioversion-resistant atrial fibrillation
intravenous vernakalant facilitated successful electrical cardioversion in patients who had failed to attain sinus rhythm following failed electrical cardioversion, or who immediately returned to atrial fibrillation after briefly attaining sinus rhythm.
Report highlights urgent action needed to lessen the future impact of atrial fibrillation in...
Report recommendations aim to improve management of atrial fibrillation as numbers are expected to double from 8.8 to 17.9 million adults aged over 55 years between 2010 and 2060.
Medtronic receives FDA approval and CE mark for Arctic Front Advance ST cryoballoon to...
The third-generation cryoballoon is designed to allow enhanced positioning and help improve capture of real-time data with achieve mapping catheter.
First patient enrolled in dabigatran study comparing anticoagulation strategies during atrial fibrillation ablation
The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa) during ablation procedures compared to warfarin. Results from the study are expected during 2016.
Abbott and GE Healthcare announce agreement to improve atrial fibrillation treatment
The agreement will bring real-time, patient-specific heart electrical activity data to cardiac electrophysiology labs around the world to speed up the diagnosis of the sources of atrial fibrillation and other heart rhythm disorders.
First-in-human study backs neuromodulation to treat paroxysmal atrial fibrillation
A first-in-human study shows low level transcutaneous electrical vagus nerve stimulation, a completely non-invasive approach, suppresses paroxysmal atrial fibrillation.
Harvard Clinical Research Institute named as a data analytic centre for PINNACLE Registry of...
The PINNACLE Registry is a cardiological outpatient quality improvement registry, which collects data about patients in participating cardiology practices to help providers evaluate and improve their adherence to current guidelines.
Atrial fibrillation recurrence lower with sleep apnoea treatment
The use of continuous positive airway pressure was associated with a significant reduction in the recurrence of atrial fibrillation in patients with obstructive sleep apnoea, according to a new analysis of data.
AATS Graham Foundation and AtriCure announce James L Cox Fellowship in atrial fibrillation surgery
Fellowship provides newly-graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognised experts in atrial fibrillation surgery.
Adding atrial fibrillation ablation to mitral valve surgery significantly increases risk of permanent pacemaker...
A new study has found that a combination of surgical atrial fibrillation ablation and mitral valve surgery in patients with persistent or long-standing persistent atrial fibrillation is associated with a significantly increased rate of freedom from atrial fibrillation at one year. However, it is also associated with a significantly increased rate of pacemaker implantation.
Catheter ablation superior to amiodarone for patients with persistent atrial fibrillation and heart failure
Speaking at the 2015 American College of Cardiology Annual Scientific Session, Luigi Di Biase reported that-compared with the antiarrhythmic drug amiodarone-catheter ablation significantly increases the rate of freedom of recurrence in patients with persistent atrial fibrillation and heart failure.
Gender, age and mood disorders affect how patients perceive atrial fibrillation symptoms
First-of-its-kind study published in HeartRhythm assesses various factors that lead to inaccurate detection of the frequency and duration of atrial fibrillation episodes.
Many atrial fibrillation patients at high risk of stroke fail to receive guideline-recommended oral...
First phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA-AF Registry programme.
Atrial fibrillation patients on digoxin face increased risk of death
Analysis of 19 studies finds atrial fibrillation patients taking digoxin are 27% more likely to die than those who do not.
Global atrial fibrillation treatment market to peak at US$9.4bn in 2020
The market will more than double in value from US$4.6bn in 2013 to US$9.4bn in 2020, before declining to US$5.7bn by 2023, according to research and consulting firm GlobalData.
Real-world study shows effectiveness of Reveal LINQ to detect atrial fibrillation in cryptogenic stroke...
New data demonstrate cost-effectiveness of long-term, continuous cardiac monitoring with potential to prevent recurrent strokes.
FDA approves Savaysa for reduction of stroke risk in non-valvular atrial fibrillation and for...
Savaysa (edoxaban) is an oral, once-daily selective factor Xa inhibitor, designed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Get With The Guidelines-AFIB: A US quality improvement programme for atrial fibrillation patients
Guideline adherence to anticoagulation in atrial fibrillation seems to be more difficult compared to other quality measures in cardiology practice. William Lewis (chair of...
AliveCor launches atrial fibrillation algorithm detector for its Heart Monitor
The latest version of the AliveECG app for users in the United Kingdom and Ireland now provides patients with real-time atrial fibrillation detection in electrocardiogram recordings using the AliveCor Heart Monitor.
Medtronic initiates European trial to evaluate cryoballoon ablation treatment for atrial fibrillation
Cryoablation creates lesions by freezing tissue in the heart's upper chambers, traditionally around the pulmonary veins, to block the electrical signals that trigger erratic heart rhythms.
Non-invasive mapping prior to ablation may be an effective strategy for persistent atrial fibrillation
Preliminary data from the AFACART study have shown encouraging results when treating persistent atrial fibrillation with non-invasive mapping followed by pulmonary vein isolation and/or linear lesions.
European cardiologists highlight risk of delayed diagnosis for patients with non-valvular atrial fibrillation
A new survey has found that despite an increase in the number of non-valvular atrial fibrillation patients compared to five years ago, the majority of cardiologists believe there is a delay in patients reaching diagnosis.
Watchman presents possible alternative to warfarin for stroke prevention in patients with atrial fibrillation
Study examines the long-term efficacy and safety of Boston Scientific's Watchman device to achieve left atrial appendage closure in patients with atrial fibrillation.
Survey uncovers need to raise awareness of link between atrial fibrillation and the impact...
A survey issued by the Heart Rhythm Society and National Stroke Association in collaboration with Boehringer Ingelheim has found there are information gaps regarding the impact of AF-related stroke - among AF patients, physicians and caregivers - including communication barriers, challenges with patient education, misperceptions about treatment compliance, and outcomes related to the impact of stroke on one's life.
Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results
An international multicentre registry evaluating the role of remote robotic navigation and contact force sensing in persistent atrial fibrillation (AF) treatment has found that, at one year, a higher proportion of patients treated with this modality were free from AF recurrences with a single procedure as compared with both manual/contact force sensing and robotic/no contact force sensing procedures.
Massachussets General Hospital to coordinate new global research initiative in USA exploring genetic causes...
The Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care has announced participation as coordinating centre in the USA for a new research initiative dedicated to explore the genetic causes of atrial fibrillation as part of the Transatlantic Network of Excellence in Cardiovascular and Neurovascular Research Program.
Study finds nMARQ ablation catheter fast and effective for the treatment of paroxysmal atrial...
A recent feasibility study has found irrigated multi-electrode radiofrequency ablation of atrial fibrillation using the novel 10-pole circular, open-irrigated mapping and ablation catheter nMARQ device (Biosense Webster) to be fast and effective.
John Muir Health’s Concord medical centre one of 20 hospitals in USA to use...
John Muir Health's Concord medical centre is one of just 20 hospitals in the USA to begin treating patients who suffer from atrial fibrillation with a new procedure that features the FDA-cleared FIRMap catheter.
Exercise may protect older women from atrial fibrillation
Increasing the amount or intensity of physical activity can cut the chances of older women developing atrial fibrillation, according to new research in the Journal of the American Heart Association (JAHA).
Yoga and atrial fibrillation
Dhanunjaya Lakkireddy, director, Center for Excellence in AF and Complex Arrhythmias, University of Kansas Medical Center, Kansas City, USA, explores the effects of yoga...
Is antiarrhythmic gene therapy the future of atrial fibrillation management?
Dierk Thomas (Heidelberg, Germany) writes on the results of preclinical research on antiarrhythmic gene therapy.
Moderate alcohol use associated with increased risk for atrial fibrillation
Even in moderation, consumption of wine and hard liquor may be a risk factor for atrial fibrillation, according to new research recently published in the Journal of the American College of Cardiology. The research did not identify a similar risk for moderate consumption of beer.
What is the best strategy for managing atrial fibrillation?
John D Day, president-elect of the Heart Rhythm Society writes that many cases of atrial fibrillation in the USA could be prevented or reversed with lifestyles focussed on health.
Novel oral anticoagulants an option for patients with atrial fibrillation
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
Hospital visits for atrial fibrillation rising
An 11-year study shows that hospitalisations for atrial fibrillation jumped by 23% and costs rose by 24%. The rise in atrial fibrillation's accompanying risk factors might account in part for the rise in hospitalisations.
MINERVA shows delays of persistent atrial fibrillation progression with advanced pacing feature
Results from the MINERVA (Minimize right ventricular pacing to prevent atrial fibrillation and heart failure) study have found that the Reactive ATP algorithm from Medtronic reduced the development of persistent atrial fibrillation by a 58% relative reduction compared to standard pacemakers (p<0.001).
Bariatric surgery prevents obese patients from developing atrial fibrillation
A first-of-its-kind study has found that bariatric surgery helps to prevent atrial fibrillation in patients with morbid obesity. The study was presented at the Heart Rhythm Society's 35th Annual Scientific Sessions (7-10 May, San Francisco, USA).
Antiarrhythmic drug therapy increases hospitalisation risk for older patients with atrial fibrillation and coronary...
A single centre analysis of antiarrhythmic drug therapy in older patients with atrial fibrillation and coronary artery disease has found it is associated with increased rehospitalisation at one year, and recommends safer and more effective therapies for symptom control in this group.
New atrial fibrillation Guideline covers novel anticoagulants, ablation
The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency ablation in the treatment of non-valvular atrial fibrillation, the addition of three new anticoagulants to treatment options, a diminished role in the use of aspirin, and a more comprehensive risk calculator.
Apixaban is cost-effective compared with standard of care for stroke prevention in atrial fibrillation
Based on randomised trial data and from the UK payer perspective, apixaban is a cost-effective alternative to warfarin and aspirin for stroke prevention in atrial fibrillation patients.
New onset atrial fibrillation after TAVI does not increase rate of stroke or mortality
A new study has found that new onset atrial fibrillation after transcatheter aortic valve implantation (TAVI) does not increase significantly the rate of stroke or mortality at 30-days and one-year follow-up.
10,000 patients with atrial fibrillation now enrolled in GLORIA-AF registry
The GLORIA-AF registry is expected to provide meaningful knowledge on the global role and use of antithrombotic treatments in protecting patients with atrial fibrillation from the devastating effects of stroke.
Subanalysis of phase 3 ARISTOTLE shows apixaban reduced risk of stroke vs. warfarin in...
The subanalysis shows that apixaban was more effective than warfarin in reducing the risk of stroke or systemic embolism, was associated with less major bleeding, less total bleeding and less intracranial haemorrhage, regardless of age and in reducing all-cause mortality across age groups.
Detection of atrial fibrillation with insertable cardiac monitors is superior to standard monitoring in...
Results from the CRYSTAL AF trial have shown that atrial fibrillation in patients with cryptogenic stroke is better detected with insertable cardiac monitors than standard monitoring at six, 12 and 36 months.
Apama Medical announces claim coverage in China for electrode-based ablation balloon for the treatment...
Apama Medical announced receipt of a Chinese notice of allowance for claims covering their low profile electrode assembly that enables the attachment of flexible electrodes to an ablation balloon for energy delivery and monitoring.
Vernakalant demonstrates 74% cardioversion in post-cardiac surgery patients with atrial fibrillation
A poster presented at the 43rd Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery has shown that vernakalant (Brinavess, Cardiome) successfully cardioverted 74% of atrial fibrillation patients to sinus rhythm at 90 minutes.
Aspirin still overprescribed for stroke prevention in atrial fibrillation
According to a recent study, aspirin is still overprescribed for stroke prevention in atrial fibrillation despite the potential for dangerous side effects.
New combined mapping and ablation system for atrial fibrillation treatment undergoes testing
Hans Kottkamp, Zurich, Switzerland, presented a new device strategy that combines diagnostic and treatment capabilities for atrial fibrillation in one system, at the AF Symposium in Orlando USA (9-11 January 2014). He spoke to Cardiac Rhythm News about the combined system.
Ablation of persistent atrial fibrillation, are we there yet?
Mark Earley (London, UK) argues that despite the breathtaking progress of interventional electrophysiology in the last 10 years, ablation of persistent atrial fibrillation remains an unconquered summit.
VICTORY AF trial for persistent or long-standing atrial fibrillation starts enrolment
The study will evaluate the safety of the Phased Radiofrequency system (Medtronic) for the treatment o patients with persistent or long-standing atrial fibrillation.
Depression more common in patients with persistent atrial fibrillation than in patients with paroxysmal...
Researchers in Germany have reported that depressed mood tends to be more severe in patients with persistent atrial fibrillation than in patients with paroxysmal atrial fibrillation. The study comparing populations from two large, recent, controlled clinical trials in atrial fibrillation was published ahead-of-print in Europace.
New atrial fibrillation classification by ECG will help GPs deliver personalised treatment
A new classification of atrial fibrillation (AF) by electrocardiogram (ECG) is set to be developed by European experts to aid personalised management of condition.
Management of atrial fibrillation still suboptimal in Europe
Results of EORP-AF, a pilot registry on the management and treatment of atrial fibrillation in Europe, have shown that compliance with treatment guidelines for atrial fibrillation patients with the lowest and higher stroke risk scores remains suboptimal.
Multicentre study finds focal impulse and rotor mapping (FIRM) may eliminate atrial fibrillation
Preliminary results of a new multicentre study have found that both paroxysmal and persistent atrial fibrillation may be sustained by localised stable rotors and that targeted ablation of those sources by focal impulse and rotor mapping (FIRM) can eliminate atrial fibrillation
Phase IIb study of vanoxerine shows strong safety efficacy signals for treatment of atrial...
ChanRx has announced positive safety and statistically significant efficacy data from a phase IIb study of vanoxerine (GBR-12909), a drug in development for the treatment of atrial fibrillation. The data were presented yesterday at the American Heart Association 2013 Scientific Sessions (16-20 November, Dallas, USA).
Late-breaking trial results show significant delay in atrial fibrillation disease progression with Medtronic’s pacing...
New research shows that pacemakers with enhanced-pacing features (Medtronic) have the ability to slow the progression of atrial fibrillation in patients with bradycardia, or a slow heartbeat.
Edoxaban not inferior to warfarin in stroke prevention for atrial fibrillation patients
Results from the ENGAGE AF-TIMI 48 clinical trial have found that the investigational, oral, once daily direct factor Xa-inhibitor edoxaban (Lixiana, Daiichi-Sankyo) met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.
Weight reduction decreases severe atrial fibrillation symptoms
A new study published in the Journal of the American Medical Association has shown that a structured weight reduction programme for highly symptomatic atrial fibrillation patients helps to reduce symptom burden and severity and also helps to reduce antiarrhythmic drug use.
Resveratrol derivative shows promise in treating atrial fibrillation
A new study published in the British Journal of Pharmacology has shown that a new medication based on resveratrol-a compound found in red wine and nuts-is an effective inhibitor of several potential targets involved in atrial fibrillation development. Cardiac Rhythm News spoke to Peter Light, lead author of the study.
NATF launches atrial fibrillation action initiative
The North American Thrombosis Forum (NATF) has launched an innovative educational initiative on risk assessment and anticoagulation for stroke prevention in atrial fibrillation.
Clinical strategies for selecting oral anticoagulants in atrial fibrillation patients
With the advent of new oral anticoagulants, there are many questions towards selection of the most appropriate treatment for patients with atrial fibrillation. Sean D Pokorney (Durham, USA) writes for Cardiac Rhythm News about the different clinical strategies to take into consideration based on the results of landmark clinical trials of novel oral anticoagulants.
2010 ESC guidelines on atrial fibrillation followed by seven European countries, PREFER in AF...
The guideline-recommended use of oral anticoagulation has increased compared to previous registries, as well as the use of antiarrhythmic drugs and catheter ablation procedures. Data have recently been published in Europace
What is the success rate for atrial fibrillation ablation?
Darryl Wells of the Swedish Heart and Vascular Institute, Seattle, USA, talks about how safe the ablation procedure is and how important getting patients...
Heart failure patients experience 46% reduction in atrial fibrillation risk with AdaptivCRT feature in...
On 23 September, Medtronic announced clinical trial results showing that heart failure patients treated with its AdaptivCRT feature experienced a 46% reduction in atrial fibrillation risk.
Delayed enhancement-MRI detected atrial fibrosis could predict successful ablation in atrial fibrillation
Atrial fibrosis detected using delayed enhancement magnetic resonance imaging (DE-MRI) seems to be an independent predictor of procedural outcome in patients undergoing ablation of atrial fibrillation, according to results of the DECAAF (Delayed enhancement-MRI determinant of successful catheter ablation of atrial fibrillation) study
Catheter ablation may reduce stroke risk in atrial fibrillation patients
A first of its kind study has shown that patients with atrial fibrillation who undergo catheter ablation have a lower stroke risk than patients who do not undergo the procedure independent of CHADS2 score.
Personalised atrial fibrillation management needed to close mortality gap
Personalised management is the only way to close the mortality gap for patients with atrial fibrillation, according to an ESC consensus paper presented at ESC Congress 2013 by Paulus Kirchhof (UK).
Discrepancies found in antiarrhythmic drug prescriptions for atrial fibrillation
Chern-En Chiang, General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, and colleagues, investigated the appropriate uses of antiarrhythmic drugs in atrial fibrillation patients and reported that there were inconsistencies in drug prescription compared to guidelines issued in 2006.
How to prevent complications of catheter ablation for atrial fibrillation
John D Day (Murray, USA) has performed more than 3,000 catheter ablation for atrial fibrillation procedures. Based on his experience, he describes five basic principles to minimise the risk of serious complications.
First patients enrolled in new study design of ARTISAN-AF trial for the treatment of...
ARTISAN-AF study is a pivotal clinical trial evaluating the use of Hansen Medical's Artisan family of control catheters with its Sensei X Robotic Catheter System for treatment of atrial fibrillation.
Treatments to prevent stroke in atrial fibrillation patients
Patrick Ellinor, director Cardiac Step Down Unit, Massachusetts General Hospital Corrigan Minehan Heart Centre (Boston, USA) discusses different treatment options to prevent stroke in...
Quality of life overestimated or underestimated in 55% of paroxysmal atrial fibrillation patients
A substudy from the ANTIPAF trial has found that quality of life was overrated or underrated by physicians in 55% of patients with paroxysmal atrial fibrillation. Depression was the major contributor to a higher likelihood of overrating.
Dabigatran shows sustained benefit in difficult to treat patients with atrial fibrillation and symptomatic...
Results from a new sub-analysis of the RE-LY trial support consistent benefit of dabigatran (Pradaxa, Boehringer Ingelheim) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation and previous symptomatic heart failure.
Is atrial fibrillation a genetic condition?
Despite the widespread nature of atrial fibrillation, our understanding of the disease remains limited according to Patrick T Ellinor, director Cardiac Step Down Unit, Massachusetts General Hospital Corrigan Minehan Heart Centre (Boston, USA) and associate professor, Harvard Medical School. He spoke to Cardiac Rhythm News about current research on genetics of atrial fibrillation.
The impact of radiofrequency ablation for atrial fibrillation on the gastrointestinal system
There have been a number of studies conducted to assess the efficacy and adverse effects of radiofrequency ablation of atrial fibrillation, but very little data is available on the effect of radiofrequency ablation on the upper gastrointestinal system. Dhanunjaya Lakkireddy, Kansas City, USA, reviews this subject based on the results of a new systematic approach the AF GUT study.
First pulmonary vein isolation procedure combined with renal denervation for atrial fibrillation treatment performed...
According to a Mass General press release, this is the first hospital in New England -and the second in the USA-to pair renal artery sympathetic denervation with pulmonary vein isolation for patients with atrial fibrillation and hypertension.
Complete pulmonary vein isolation more effective in atrial fibrillation treatment
Complete linear lesions when using catether ablation to isolate pulmonary veins have been shown to be more effective than incomplete lesions in preventing recurrence of atrial fibrillation, according to results from the GAP-AF study presented at a late-breaking trial session of the European Heart Rhythm Association (EHRA) Europace meeting (23-26 June, Athens, Greece).
Multicentre European study set to evaluate HeartLight system for persistent atrial fibrillation
A study is to be the first to prospectively assess the outcomes of pulmonary vein isolation with balloon ablation catheters in patients with persistent atrial fibrillation, according to a company release.
Ablation superior to medical therapy for patients with persistent atrial fibrillation
According to results from the SARA study, presented at a late-breaking trial session of the European Heart Rhythm Association (EHRA) Europace meeting (23-26 June, Athens, Greece), catheter ablation therapy has been shown to be superior to medical therapy for maintenance of sinus rhythm in patients with persistent atrial fibrillation.
New risk assessment tool to predict stroke in patients with atrial fibrillation
Model will give physicians more reliable guidance in making therapeutic decisions for stroke prevention.
Promising mid-term results from thoracoscopic ablation of persistent atrial fibrillation
At three-year follow-up, 80% of patients with persistent atrial fibrillation showed freedom from atrial fibrillation and were free from anti-arrhythmic drugs after thoracoscopic ablation with the Bipolar RF Ablation System (AtriCure).
RELY-ABLE results support long-term safety of dabigatran in non-valvular atrial fibrillation patients
Results from the RELY-ABLE trial, a long-term extension of the pivotal RE-LY study of dabigatran (Pradaxa / Boehringer Ingelheim) in patients with non-valvular atrial fibrillation, have provided additional information showing long-term safety of dabigatran.
Effectiveness of left atrial appendage exclusion, ligation and occlusion in reducing stroke risk in...
Andre d'Avila and Arash Aryana write on three different left atrial appendage strategies aimed to reduce stroke risk in atrial fibrillation patients. d'Avila presented this analysis at Heart Rhythm (Denver, USA, 8-5 May 2013).
Targeted ablation without pulmonary vein isolation shows 82% single procedure success rate in paroxysmal...
A late breaking trial presented at Heart Rhythm 2013 (8-11 May, Denver, USA) has demonstrated that targeted ablation of stable rotors and focal sources can eliminate paroxysmal atrial fibrillation without the need to isolate the pulmonary veins.
Atrial fibrillation may be reduced in sleep apnoea patients using airway pressure therapy and...
Continuous positive airway pressure may help to reduce atrial fibrillation recurrence in patients with obstructive sleep apnoea undergoing pulmonary vein isolation, a study published ahead of print in the Journal of the American College of Cardiology (JACC) has found.
Leading physicians launch avert-AF initiative to develop drug treatment for atrial fibrillation
Cardiovascular scientists from the University of Michigan, USA, and St George's University of London, UK, announced the launch of avert-AF, a new initiative aimed at developing drug treatments for the prevention of the more advanced forms of atrial fibrillation.
Electrocardiographic abnormality associated with increased risk of atrial fibrillation, congestive heart failure
Left anterior fascicular block may be a clinically relevant marker of an individual's propensity to develop atrial fibrillation or congestive heart failure, a new study has found.
Zio Patch shows improved paroxysmal atrial fibrillation detection compared with 24-hour Holter Monitor
Zio Patch, anambulatory cardiac monitoring system (iRhythm), has shown benefit of long-term monitoring or paroxysmal atrial fibrillation patients and significant impact on treatment strategy.
HeartLight Endoscopic Ablation System to be highlighted at Frankfurt Atrial Fibrillation Academy 2013
The Annual Frankfurt Atrial Fibrillation Academy Symposium will highlight the latest innovations and research in atrial fibrillation therapy.
Isis Pharmaceuticals initiates phase 2 study of ISIS-CRP(Rx) in atrial fibrillation patients
ISIS-CRP(Rx) is being evaluated in patients with atrial fibrillation to measure the effect of lowering C-reative protein on the frequency and duration of the episodes.
UK’s NICE publishes final guidance recommending apixaban to prevent stroke in non-valvular atrial fibrillation...
On 27 February, the UK's National Institute for Health and Clinical Excellence (NICE) released final guidance recommending apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.
Americans ignore warning signs of atrial fibrillation, a new survey from the Heart Rhythm...
The Heart Rhythm Society calls on all Americans to know risks and warning signs of the most common arrhythmia during February the Heart Health Month.
The Scottish Medicines Consortium accepts apixaban for prevention of Stroke in non-valvular atrial fibrillation...
The Scottish Medicines Consortium has accepted the novel oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb / Pfizer) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
Yoga helps atrial fibrillation patients
A first-of-its-kind study by Dhanunjaya Lakkireddy, Kansas, USA, and others has found that rigorous practice of yoga can help reduce episodes of irregular heartbeat and improve the symptoms of anxiety and depression often associated with atrial fibrillation.
Update on GENETIC-AF trial for Gencaro in Atrial Fibrillation
GENETIC-AF is projected to be a 620-patient, phase 3 study comparing Gencaro (ARCA biopharma) to metoprolol CR/XL for prevention of atrial fibrillation in patients with heart failure and left ventricular dysfunction.
Faster lower pacing rate after atrioventricular node ablation may help to decrease sudden death...
Faster lower pacing rate immediately after atrioventricular node ablation with a gradual decrease helps to improve clinical outcome and may reduce the risk of sudden death in patients with atrial fibrillation, Ru-Xing Wang and other reported in Heart Rhythm ahead of print.
Biotronik to start MATRIX study to explore improved detection and management of atrial fibrillation
MATRIX is a prospective open study that will include 2,000 patients in 100 sites throughout Europe, Latin America, Canada, Israel and Japan for up to four years.
Are patients with atrial fibrillation at increased risk of developing dementia?
Pasquale Santangeli, Texas Cardiac Arrhythmia Institute, St David's Medical Centre, Austin, USA, spoke to Cardiac Rhythm News about the link between atrial fibrillation and dementia.
NICE recommends apixaban for some people with non-valvular atrial fibrillation
On 23 January, the UK's National Institute for Health and Clinical Excellence (NICE) issued a final draft guidance recommending apixaban (Eliquis, Bristol-Myers Squibb and Pfizer), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation.
NICE guidance supports new blood pressure device that can detect atrial fibrillation
New NICE medical technologies guidance published on 16 January 2013 supports the use of a device that can detect atrial fibrillation whilst blood pressure is being measured.
New clinical trial will use continuous cardiac monitoring to evaluate atrial fibrillation in high-risk...
Medtronic has announced the first patient implant for the REVEAL AF trial, which will evaluate the incidence of AF among patients suspected to be at a high-risk for the disease.
Over 1,000 atrial fibrillation cases performed with the HeartLight ablation system
CardioFocus has announced that more than 1,000 clinical cases have been performed worldwide using its HeartLight Endoscopic Ablation System technology for the treatment of atrial fibrillation.
Minimally invasive hybrid ablation is safe and effective for treatment for atrial fibrillation patients
One year after treatment completion, 80% of patients in normal sinus rhythm without administration of drugs, study says.
Apixaban now available in the UK for the prevention of stroke and systemic embolism...
The oral anticoagulant is a new prescription only treatment option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors such as: prior stroke or transient ischaemic attack; age 75 years or older; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Mobile Cardiac Outpatient Telemetry helps to detect paroxysmal atrial fibrillation in cryptogenic stroke patients
A study published in the Journal of the Neurological Sciences has found that Mobile Cardiac Outpatient Telemetry (MCOT) supports the detection of a high rate of occult paroxysmal atrial fibrillation (PAF) in cryptogenic stroke and transient ischaemic attack (TIA) patients.
European Commission approves apixaban for prevention of stroke and systemic embolism in non-valvular atrial...
The European approval for apixaban is supported by the pivotal phase 3 trials ARISTOTLE and AVERROES, which evaluated approximately 24,000 patients with non-valvular atrial fibrillation.
High-dose visually guided laser ablation superior to low-dose ablation in treatment of patients with...
New data have shown that acute pulmonary vein isolation was achieved after a single visually guided circular lesion set in 89% and 69% of patients in the high and low-dose groups, respectively.
HeartLight Ablation System receives unique classification code in Germany for the treatment of atrial...
Use of the new code allows the German Institute of Medical Documentation and Information to track the number of atrial fibrillation patients being treated with laser ablation guided by endovascular endoscopy and provides the initial step to receiving a specific diagnosis-related group code for the procedure.
A smart way to make community screening for atrial fibrillation feasible?
Jerrett Lau, Concord Hospital, Sydney, Australia, and others reported, at the American Heart Association (AHA) scientific sessions, that a smartphone app could be used to diagnose atrial fibrillation in a community setting.
Moderate alcohol consumption may increase risk of atrial fibrillation
Yan Liang, Beijing, China, and colleagues have found that moderate alcohol consumption may increase the risk of atrial fibrillation among people with existing cardiovascular disease and that binge drinking further increases this risk. The researchers analysed data from 30,433 patients enrolled in the ONTARGET and TRANSCEND trials.
Apixaban receives CHMP positive opinion for the prevention of stroke and systemic embolism in...
The positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) was based on the pivotal ARISTOTLE and AVERROES studies, which evaluated apixaban in approximately 24,000 patients with non-valvular atrial fibrillation.
AtriCure launches three-year post-approval study for the surgical correction of atrial fibrillation
The 350-patient study is a follow-up to the company's 14 December 2011 FDA approval of the AtriCure Synergy Ablation System for the surgical treatment of atrial fibrillation.
Obesity increases the risk of atrial fibrillation in fertile women
A study presented at the ESC annual meeting (25-29 August 2012) suggests that obesity increases the risk of atrial fibrillation in women of child-bearing age, indicating that lifestyles measures could be used to prevent the development of atrial fibrillation in this population.
Intermittent rhythm monitoring fails to identify atrial fibrillation recurrence in a great proportion of...
Efstratios Charitos, Luebeck, Germany, and colleagues have reported in Circulation that two to four sessions of 24h intermittent rhythm monitoring has been shown to "under-detect atrial fibrillation recurrence and thus overestimate success rates of therapeutic interventions".
PINNACLE-AF registry shows early patterns for new atrial fibrillation treatments
The American College of Cardiology (ACC) has released first findings from its expanded outpatient registry, the PINNACLE registry, focusing on atrial fibrillation and including the next generation of anticoagulants.
Does the hybrid procedure have the potential to treat atrial fibrillation in a single...
The hybrid procedure, which combines a transvenous endocardial and a thoracoscopic epicardial approach in a single ablation procedure, is associated with a 83% success rate at one year in patients with atrial fibrillation, a study has found.
Experts call for better management of atrial fibrillation
A new report launched on 3 July written by UK experts shows that atrial fibrillation, a condition that affects up to 1 million people in the UK, is not being optimally managed.
Convergent procedure building support for interdisciplinary approach to atrial fibrillation
An article in the Journal of Cardiovascular Electrophysiology outlines the development and results of the new interdisciplinary procedure, the convergent procedure
UK’s NICE releases final guidance on rivaroxaban for prevention of stroke and systemic embolism...
The guidance recommends rivaroxaban for people with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack.
Data presented at HRS 2012 suggest Convergent Procedure ablation may restore persistent atrial fibrillation...
nContact has announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary Convergent Procedure in the treatment of persistent atrial fibrillation (AF), with over 80% of patients remaining in sinus rhythm at a minimum of 12 months follow-up.
Palpitations are predictive of future atrial fibrillation
A large cohort study from Norway has found that the strongest risk factors for atrial fibrillation in both men and women were a history of palpitations and hypertension.
Watchman device shows 75% reduction in stroke risk in patients with atrial fibrillation not...
Vivek Reddy, New York, USA, presented results from the ASA Plavix (ASAP) study of the Watchman Left Atrial Appendage Closure (LAAC) device (Boston Scientific) during a late-breaking session at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston, USA.
Non-surgical procedure offers patients with atrial fibrillation who cannot take blood thinners an alternative...
The procedure, known as left atrial appendage occlusion, is performed using the FDA-approved Lariat Suture Delivery Device (SentreHeart).
“The future of AF ablation catheter technologies”: A new report reveals the potential of...
Design and technology consultancy Cambridge Design Partnership has announced that it has completed a research project to identify the future of medical technology to treat atrial fibrillation.
Heart Rhythm Society launches atrial fibrillation and sudden cardiac arrest awareness campaign
The Heart Rhythm Society (HRS) has launched a Boston citywide awareness campaign to increase knowledge about symptoms, warning signs and available treatment options for atrial fibrillation and sudden cardiac arrest.
Radiofrequency catheter ablation is safe and effective in the octogenarian patient with atrial fibrillation
A study published in the Journal of Cardiovascular Electrophysiology shows that catheter ablation of octogenarians with atrial fibrillation is as safe and effective as catheter ablation of atrial fibrillation in younger patients
GLORIA-AF registry to explore use of antithrombotic therapy in 56,000 patients with atrial fibrillation...
The registry programme will collect important data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist warfarin, acetylsalicylic acid and novel oral anticoagulants, such as dabigatran etexilate.
UK’s NICE recommends second new anticoagulant for atrial fibrillation
Following its recent recommendation for dabigatran (Pradaxa, Boehringer Ingelheim), the UK's National Institute for Health and Clinical Excellence (NICE) now recommends rivaroxaban (Xarelto, Bayer) as an option for preventing stroke and systemtic embolism in patients with non-valvular atrial fibrillation.
“The Convergent Procedure may improve heart function and provide a viable treatment option for...
In a study presented by Janez Toplisek, at ACC 2012, 85% of patients who underwent ablation with the multidisciplinary Convergent Procedure were in sinus rhythm at one year follow-up, had a significant reduction in left atrial size and improvement in left ventricular ejection fraction.
New study to investigate the role of early radiofrequency ablation in delaying progression of...
ATTEST, a prospective, multicentre, randomised, controlled study will compare pulmonary vein isolation (using Biosense Webster's ThermoCool catheters and the company's Carto 3 or Carto XP mapping systems) with drug therapy (rate or rhythm control) in patients with paroxysmal atrial fibrillation.
Atrial fibrillation is independently associated with cognitive and functional decline
According to a study published in the February issue of the Canadian Medical Association Journal, cognitive and functional decline are "important consequences" of atrial fibrillation even in the absence of overt stroke.
Paroxysmal atrial fibrillation may account for some unexplained strokes
Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
Middle-aged men with upper-normal blood pressure at risk for atrial fibrillation
Middle-aged men at the upper end of normal blood pressure had an elevated risk for atrial fibrillation later in life, according to new research published in Hypertension: Journal of the American Heart Association.
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, increase the risk of stroke
A new study, published in the New England Journal of Medicine, has added weight to the view that subclinical atrial fibrillation is a possible cause of cryptogenic stroke after finding that 13% of strokes and systemic embolisms in the study population were associated with subclinical atrial tachyarrhythmias.
New consensus document for atrial fibrillation ablation previewed at Boston AF
Hugh Calkins, Maryland, USA gave a sneak preview of the forthcoming 2012 document on catheter ablation for atrial fibrillation. At Boston AF he said, the new document is not just a "brief update" of the previous HRS/EHRA/ECAS document, which was published in 2007, but a "comprehensive, state-of-the-art review of the field of catheter and surgical ablation for atrial fibrillation."
Single atrial fibrillation ablation procedure achieves high pulmonary vein isolation rates, study shows
Researchers in Germany achieve 98% acute pulmonary vein isolation, with 77% of patients in sinus rhythm at approximately nine months follow-up.
Pan-European stroke prevention in atrial fibrillation registry PREFER in AF enrols first patient
The registry will gather information from valvular and non-valvular atrial fibrillation patients. It will also track the impact of new anticoagulant therapies on stroke prevention, in addition to collating insights into patients' satisfaction with their entire atrial fibrillation management and the overall health economic burden of atrial fibrillation across Europe.
Experts unveil tools to improve atrial fibrillation care
Four interventions to enhance the care and treatment of individuals with atrial fibrillation were presented on 10 January 2011 at a press briefing hosted by The American College of Physicians Foundation's initiative on atrial fibrillation and stroke prevention.
NICE needs more evidence on rivaroxaban for prevention of stroke in atrial fibrillation patients
In preliminary recommendations published on 9 January, NICE is asking Bayer HealthCare for more information on its product rivaroxaban (Xarelto), for the prevention of stroke and systemic embolism in people with atrial fibrillation.
Rhythmview system featured at Boston Atrial Fibrillation Symposium 2012
Rhythmview (Topera Medical) is a mapping system that helps identify the electrical source of cardiac arrhythmias. It will be utilised as part of a complex procedure demonstration on 12 January at the 17th Annual Boston Atrial Fibrillation Symposium.
FDA approves AtriCure’s Synergy Ablation system for atrial fibrillation treatment
AtriCure's Synergy Ablation system has been approved for the treatment of patients with persistent and long-standing persistent atrial fibrillation during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures.
The risk of atrial fibrillation with COX-2 inhibitors may have been overlooked
A new study in the European Heart Journal indicates that while restrictions on the use of cycloocygenase (COX)-2 inhibitors may have limited the feared cardiovascular consequences of the drugs, the risk of atrial fibrillation may have been overlooked and may warrant further consideration.
More work needed to reduce strokes due to atrial fibrillation in UK
A study published in BMJ Open has found that although the number of strokes has fallen in the UK, more needs to be done to reduce the risk of stroke in patients with atrial fibrillation. Additionally, it seems that while the use of anticoagulants does not increase with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score in patients with atrial fibrillation, the use of antiplatelets does increase
FDA approves rivaroxaban to prevent stroke in non-valvular atrial fibrillation patients
The Food and Drug Administration's approval is largely based on the results from the ROCKET-AF trial, a double-blind global phase III study that showed the safety and efficacy of rivaroxaban (Xarelto, Bayer Healthcare).
FDA advisory panel votes against Medtronic Phased RF Ablation System for atrial fibrillation
The majority of the panel does not believe there is reasonable assurance of the safety of Medtronic's ablation system, and that the clinical benefits of the technology do not outweigh the potential risks based on the TTOP-AF clinical trial data.
Surgical ablation system for atrial fibrillation receives recommendation from FDA expert advisors
FDA's Circulatory System Devices Panel recommended AtriCure's Synergy ablation system for the treatment of atrial fibrillation during open-heart concomitant surgical procedures.
Atrial fibrillation undertreated as one of the major risk factors for stroke in the...
Despite significant improvements in stroke prevention over the past decade, and a fall in incidence and deaths, UK doctors are still undertreating one of the major risk factors-atrial fibrillation-reveals research published in BMJ Open.
Ablation therapy in atrial fibrillation patients shows to be effective but risky
The TTOP-AF trial results showed a 90% reduction in atrial fibrillation or atrial flutter burden in 55.8% of ablation patients; however the results did not meet the pre"defined performance safety goal of 16%.
Landmark pan-European atrial fibrillation trial recruits first patient
The EAST clinical trial is the largest pan-European study to evaluate whether an early and comprehensive rhythm control treatment of patients with early onset atrial fibrillation produces better patient outcomes than usual care alone.
New study shows that cigarette smoking doubles the risk of atrial fibrillation
A large, multi-year, biracial study is first to show more than a two-fold increase of incident atrial fibrillation in current smokers compared to those who have never smoked.
ESC announces review on atrial fibrillation guidelines
Following the early termination of the PALLAS trial, the Guidelines Department of the European Society of Cardiology (ESC) has issued a new statement with regards to the use of dronedarone in atrial fibrillation patients, in accordance with advice given by the European Medicines Agency and the US Food and Drug Administration.
Atrial fibrillation is emerging as the new epidemic
Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with AF remain unacceptably high, according to a joint report by the German Competence Network on Atrial Fibrillation (AFNET) and the European Heart Rhythm Association (EHRA).
Novel mapping system identifies sources causing atrial fibrillation
Results from the CONFIRM trial showed that a targeted, single procedure ablation at identified sources increased the long-term freedom from atrial fibrillation by 70% over the existing standard of care.
Biosense starts enrolment for the REVOLUTION study for the treatment of paroximal atrial fibrillation
REVOLUTION is a prospective, multicentre, non-randomised clinical study for the evaluation of a multi-electrode pulmonary vein isolation system used to treat paroxysmal atrial fibrillation.
Does moderate alcohol consumption increase the risk of atrial fibrillation?
Even moderate alcohol consumption can lead to the development of atrial fibrillation, according to researchers from the University of Tsukuba, Institute of Clinical Medicine, Mito, Japan.
Atrial fibrillation and dementias
Jared Bunch, cardiologist and electrophysiologist, Intermountain Medical Centre, Utah, USA, explained to Cardiac Rhythm News how atrial fibrillation is independently linked to memory impairment, cognitive decline, and general dementia.
Mount Sinai performs first US cardiac ablation using contact force-sensing catheter to treat atrial...
The first catheter ablation procedure was performed at the end of February by Vivek Y. Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Heart and colleagues.
Apixaban superior to aspirin in reducing stroke and systemic embolism in patients with atrial...
Bristol-Myers Squibb and Pfizer announced the full results of the AVERROES study of apixaban in The New England Journal of Medicine.
Mayo Clinic first in USA to use newly approved FDA technology to treat atrial...
"This approach provides a single ablative means of eliminating problematic atrial fibrillation in patients who failed drug therapy," said Douglas Packer, cardiologist at Mayo Clinic.
New trial studies link between stroke and atrial fibrillation
The CRYSTAL AF trial will enrol approximately 450 people who have been diagnosed with a cryptogenic stroke across 55 centres.
FDA approves dabigatran to prevent stroke in atrial fibrillation patients
The FDA approved on 19 October 2010 dabigatran etexilate (Pradaxa, Boehringer Ingelheim) for the prevention of stroke and blood clots in patients with atrial fibrillation.
FDA advisory committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial...
Dabigatran etexilate may offer patients and doctors the first new treatment option for stroke prevention in atrial fibrillation in more than 50 years.
STOP-AF shows cryoablation prevents atrial fibrillation better than drugs
Professor Douglas Packer presents the results of two clinical trials conducted using the cryoablation technique.
Draft NICE guidance unable to recommend dronedarone for atrial fibrillation
"The evidence provided to the independent appraisal committee indicates that dronedarone is less effective and costs considerably more than existing treatments for controlling AF," the agency wrote.
Dronedarone approved in the European Union for patients with atrial fibrillation
Multaq, developed by Sanofi-aventis, is the first new anti-arrhythmic drug to be approved in Europe in the last 10 years.
Call for more studies on new agents for atrial fibrillation
We have many drugs available to us that could eventually come to clinical trials, but there are very few studies ongoing at the moment, John Camm said at the Venice Arrhythmias symposium.
Cost-effectiveness of atrial fibrillation catheter ablation
Panos E Vardas, president of the European Heart Rhythm Association, analyses the trend on expanding the existing indications and usage of ablation.
Copy of FDA approves dronedarone for patients with atrial fibrillation or atrial flutter
Approved to reduce the risk of cardiovascular hospitalization, Multaq will be launched this summer in the US by Sanofi-aventis.
AF AWARE calls for greater awareness and better education on atrial fibrillation
Survey shows many doctors find the management of atrial fibrillation difficult and patients are unaware of risks, complexities and treatment.
Big men more susceptible to atrial fibrillation
Study shows that older men who were big during their 20s face an increased risk of suffering from atrial fibrillation.
Valsartan fails against atrial fibrillation recurrence
Study showed that atrial fibrillation recurred in 51.4% of patients in the drug group, as compared with 52.1% in the placebo group.
Novel device cuts stroke risk in patients with atrial fibrillation
The Watchman, an expandable nitinol cage which blocks blood clots that typically form in the left atrial appendage, may offer alternative to blood-thinning medications.
Increasing use of ablation to treat atrial fibrillation
American report says number of catheter ablation procedures for treating atrial fibrillation will fuel revenues in the electrophysiology ablation catheter market over the next five years.
New technology used to treat atrial fibrillation
The Texas Cardiac Arrhythmia Institute, Austin, became the first in the United States to utilise the long-awaited NaviStar ThermoCool Catheter.
New simulations show weak electrical pulses could treat atrial and ventricular fibrillations
With numerical simulations, researchers have demonstrated a new way to time weak electrical pulses that can stop certain life-threatening arrhythmias. Publishing their work in...
First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery...
AtriCure has announced that the first patient was treated in the LeAAPS clinical trial, a prospective, randomised clinical trial to evaluate the safety and...
Measurement of left atrial mechanical function found to improve stroke prediction
A cohort study of more than 4,500 persons without a history of atrial fibrillation (AF) or stroke has found that measuring left atrial mechanical...
LeAAPS trial to explore benefit of left atrial appendage occlusion in cardiac surgery patients...
Researchers are to investigate the safety and efficacy of performing left atrial appendage occlusion in patients at high risk for atrial fibrillation (AF) who...
Contact force-guided ablation for typical atrial flutter does not reduce recurrent atrial arrhythmia
Contact-force (CF)-guided ablation to treat typical atrial flutter does not reduce recurrent atrial arrhythmia at 12 months follow-up, in comparison to ablation blinded for...
Targeting atrial fibrosis in AF patients with low levels of disease “may help improve...
Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ablation success rates compared to PVI alone in patients with persistent...
PRECAF study looks at elimination of distal coronary sinus to left atrial connection for...
Elimination of distal coronary sinus (CS) to left atrial (LA) connections reduced atrial arrhythmia recurrences compared to standard pulmonary vein (PV) isolation and non-PV...
PCR e-Course 2020: Left atrial appendage occlusion improves clinical outcomes versus NOACs in high...
Left atrial appendage occlusion (LAAO) improves clinical outcomes including ischaemic stroke, major bleeding and all-cause mortality, in atrial fibrillation (AF) patients with a high...
Virtual ACC: Largest left atrial appendage occlusion registry finds Watchman acute safety data “very...
Data from the National Cardiovascular Data Registry (NCDR) Left Atrial Appendage Occlusion (LAAO) Registry, which enrolled more than 38,000 patients implanted percutaneously with the...
Novel device “safely obliterates” left atrial appendage with minimal amount left behind
The novel left atrial appendage (LAA) closure device Appligator (Append Medical) was a finalist in the 2019 ICI Innovation Award Competition (Innovation in Cardiovascular...
Left atrial appendage closure associated with a decreased stroke risk in AF patients
Left atrial appendage closure (LAAC) via implanted device was associated with a decreased risk of admission for stroke, compared with the expected risk without...
Decline in defibrillation testing during ICD implantation is due to institutional rather than patient...
The use of defibrillation testing (DFT) when inserting an implantable cardioverter defibrillator (ICD) declined significantly in US hospitals between 2010 and 2015; during the...
ESC 2019: Left atrial appendage closure is non-inferior to NOACS for preventing neurological events
At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Pavel Osmancik (Charles University and University Hospital Kralovske Vinohrady, Prague,...
Boston Scientific initiates trial comparing left atrial appendage closure to direct oral anticoagulants for...
According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial...
Smart watch can identify undetected fibrillation
An app on a smartwatch can be used to detect atrial fibrillation, providing a boost for the role of digital technology in healthcare.
Mintu Turakhia...
CE mark for Watchman FLX left atrial appendage closure device
Boston Scientific announced it has received CE mark and initiated a limited market release of the next generation Watchman FLX left atrial appendage closure...
Simultaneous TAVI and left atrial appendage closure is feasible
Thomas S Gilhofer (University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland) and others report in Structural Heart that a combined procedure...
Novel Ultraseal device is a feasible option for left atrial appendage closure
A feasibility study of a novel left atrial appendage device (Ultraseal, Cardia) indicates that the device is associated with a high rate of procedural...
Re-evaluate use of anticoagulation in patients with atrial flutter
A new study, published in JAMA Network Open, indicates that patients with atrial flutter have a lower incidence of stroke than patients with atrial...
Thoracoscopic ablation and left atrial appendage excision found to be superior to catheter ablation...
Symptomatic atrial fibrillation (AF) patients with previous failed catheter ablation or structural changes associated with higher recurrence of AF could benefit from thoracoscopic ablation...
Octreotide enables left atrial appendage closure in AF patients with GI bleeding
Octreotide therapy has the potential to offer atrial fibrillation (AF) patients with arteriovenous malformations (AVM) related gastrointestinal (GI) bleeding another treatment option. It is...
Association found between left atrial appendage closure and readmission for thromboembolism
A collaborative study, has found that older patients with atrial fibrillation (AF) undergoing cardiac surgery accompanied with surgical left atrial appendage closure had a...
Left atrial appendage closure during heart surgery protects the brain from ischaemic events
Closure of the left atrial appendage during open heart surgery protects the brain from infarctions and stroke, and could be routinely performed in the future,...
Europace 2017: Thrombus formation on left atrial appendage occlusion devices strongly associated with higher...
A French multicentre analysis of left atrial appendage (LAA) occlusion for stroke prevention in atrial fibrillation patients has found a 5.3% rate of thrombus...
Surgical left atrial appendage occlusion reduces thromboembolic stroke and mortality in older AF patients
Surgical left atrial appendage occlusion (LAAO) is associated with a reduction of thromboembolism and all-cause mortality among older atrial fibrillation (AF) patients undergoing cardiac...
Occlutech left atrial appendage occluder shows high procedural success in first-in-man experience
The first-in-man study exploring the safety, feasibility and neurological outcome with the Occlutech left atrial appendage (LAA) occluder (Occlutech) has shown a 93% procedural...
St Jude Medical launches trial of Amplatzer Amulet left atrial appendage occluder
The St Jude Medical Amplatzer Amulet Investigational Device Exemption (IDE) trial, which will evaluate the safety and effectiveness of the company’s Amplatzer Amulet left...
CE mark granted to Occlutech left atrial appendage occluder
Occlutech has obtained European CE mark approval for its left atrial appendage, (LAA), occluder.
The device is a specifically designed implant for the minimally...
Study suggests major clinical benefit for left atrial appendage occlusion
St Jude Medical has announced results from two cardiovascular clinical trials presented at EuroPCR 2016. The studies, which look at how St Jude Medical’s...
Left atrial appendage isolation with cryoballoon may work as an adjunctive strategy for persistent...
Researchers in Turkey have found that additional left atrial appendage (LAA) isolation using second generation cryoballoon technology is feasible and safe and that it may be considered as an adjunctive therapy to pulmonary vein isolation for persistent atrial fibrillation (AF) treatment.
US Medicare to cover Boston Scientific Watchman left atrial appendage closure device
The US Centers for Medicare and Medicaid Services (CMS) are to cover percutaneous left atrial appendage closure (LAAC) therapy under specific criteria, as outlined...
Advances in left atrial appendage occlusion and peri-procedural challenges
Dhiraj Gupta (Liverpool, UK) overviews developments in two left atrial appendage (LAA) occlusion devices, which have helped make the implant procedure safer, easier and quicker. He also highlights current challenges related to overall peri-procedural patient management.
An interventional cardiologist’s view on left atrial appendage closure
By Martin W Bergmann
Martin W Bergmann is an interventional cardiologist working in Germany, who performs percutaneous left atrial appendage (LAA) closure procedures. He explores...
Role of rotors in mapping and ablation of ventricular fibrillation
In recently published studies, modulation of rotors by ablation seems to be effective in termination of atrial fibrillation. Now, researchers are exploring the role of rotors in ventricular fibrillation. Siva K Mulpuru (Mayo Clinic, Rochester, USA), discusses the latest research in this field.
Electrical left atrial appendage isolation helps to improve freedom from long-standing persistent AF
A randomised, multicentre study has found improvement in the long-term freedom from long-standing persistent atrial fibrillation (AF) in patients who underwent an ablation plus empirical electrical left atrial appendage isolation strategy. No major complications were reported.
New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes
The Atrial Fibrillation Network (AFNET) association and the European Society of Cardiology (ESC) are initiating a new trial (NOAH – AFNET 6) investigating whether...
Off-label use of the Lariat device for left atrial appendage exclusion questioned
A Food and Drug Administration (FDA) announcement and a study in JAMA Internal Medicine about use of the Lariat suture delivery device (SentreHeart) for left atrial appendage (LAA) closure have raised questions regarding using the device in this off-label indication.
FDA reports adverse events with the Lariat device for left atrial appendage closure
The US Food and Drug Administration has issued a safety communication to healthcare providers reporting deaths and serious adverse events with the use of the Lariat Suture Delivery Device (SentreHeart) and its associated devices used for left atrial appendage closure.
Data shows advantages of Acutus Medical Dipole Density Heart Imaging and Mapping System in...
The data was presented at the Heart Rhythm Society's 36th Annual Scientific Sessions (13-16 May, Boston, USA) and shows the systems benefits compared with standard voltage-based mapping in patients with atrial flutter.
Targeting the left atrial appendage for AF-related stroke prevention: Why the heart team is...
Sacha Salzberg cardiovascular surgeon (Heart Clinic Hirslanden, Cardiac Surgery Unit, Zurich, Switzerland) comments on catheter-based and surgical approaches for left atrial appendage occlusion as...
Real-world multicentre study shows positive outcomes with left atrial appendage occlusion for stroke prevention...
The largest study using the Amplatzer Cardiac Plug (St Jude Medical) for left atrial appendage occlusion has shown a high procedural success rate and favourable outcomes for prevention of atrial fibrillation-related thromboembolism.
AtriCure launches AtriClip Flex for left atrial appendage occlusion
Atricure has announced the introduction of the AtriClip Flex, a new device used in left atrial appendage occlusion for stroke prevention in atrial fibrillation patients. According to a company release, the device has a more flexible aluminum shaft that allows surgeons to better manoeuvre within a patient's particular anatomy.
Antithrombotic therapy after left atrial appendage closure
Uncertainty exists about the optimal post-interventional antithrombotic drug regimen as well as treatment duration after left atrial appendage closure; Boris Schmidt and KR Julian...
Lariat device shows high rate of acute left atrial appendage closure but faces procedural...
A first US multicentre registry with the Lariat device (SentreHeart) for left atrial appendage ligation has shown 94% acute closure rate; however, procedural success has been limited with major bleeding.
Rivaroxaban prevents prothrombogenic remodelling of human atrial myocardium
Andreas Goette (Paderborn, Germany) explains the results of a study which found how rivaroxaban (Xarelto, Bayer Healthcare) helps to prevent prothrombogenic remodelling of human atrial myocardium.
FDA advisory panel votes favourably on Watchman left atrial appendage closure device
On 11 December, the FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favourably by a majority, Yes: 13, No: 1, that the benefits of the Watchman left atrial appendage closure device outweigh the risks.
Does the anatomy of left atrial appendage correlate with the risk of stroke?
Luigi Di Biase writes for Cardiac Rhythm News on the results of a study that identified four different left atrial appendage morphologies and its relationship with the risk of stroke in atrial fibrillation patients. "These results could have a relevant impact on the oral anticoagulation management and occlusion device management of atrial fibrillation patients with an intermediate risk for stroke," writes Di Biase.
FDA approves first single-lead ICD with atrial sensing
The Lumax 740 DX System from Biotronik expands the diagnostic capabilities of a standard single-chamber ICD with a single lead, in addition to featuring sophisticated sensors that allow for atrial monitoring and enhanced arrhythmia diagnosis.
Long-term results of PROTECT AF confirm left atrial appendage closure is non-inferior to warfarin
Vivek Y Reddy, Mount Sinai School of Medicine, New York, USA, and others recently reported the updated results ahead of print in Circulation.
St Jude Medical receives the CE mark for the Amplatzer Amulet Left Atrial Appendage...
The Amulet device is used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation.
Percutaneous left atrial appendage suture closure can be performed effectively, study shows
Krzysztof Bartus, Krakow, Poland, and colleagues have reported that left atrial appendage closure for stroke prevention in patients with atrial fibrillation using a percutaneous ligation approach can be performed effectively and is associated with a low rate of complications.
Watchman Left Atrial Appendage Closure Device receives CE mark approval for expanded use
The Watchman device (Boston Scientific) is indicated to be used in patients with atrial fibrillation and a contraindication to warfarin and the newer oral anticoagulants.
Measuring both left atrial size and the amount of left atrial fibrosis may improve...
A study, published in Heart, indicates that the combined assessment of left atrial size and the amount of left atrial fibrosis may improve the identification of patients who have a high likelihood of successful ablation.
Developing a business case for the left atrial appendage occlusion device
Tim Betts, UK, outlined a business case, at the Heart Rhythm congress (2-5 October 2011, Birmingham, UK) to put to commissioners, for using the percutaneous left atrial appendage (LAA) occlusion device (Watchman, Boston Scientific) for stroke prevention in patients with atrial fibrillation.
First atrial flutter patient treated with novel MRI ablation catheter
The development of this novel catheter, specially designed to be used with magnetic resonance imaging, could represent a significant new opportunity for improved therapy of complex cardiac arrhythmias.
New defibrillation method may lead to less pain
The new method, developed by Cornell University scientists, terminates the turbulent electrical activity within the heart. The weak electrical signals create "virtual electrodes" that stimulate heterogeneities within the heart and, particularly, the blood vessels.
Medtronic announces trial of therapy for closure of the left atrial appendage
Study in the USA will evaluate the Cardioblate Closure, a device intended to occlude the LAA permanently without introducing man-made materials into the blood stream.
Seventy-fifth patient enrolled in GENETIC-AF bucindolol trial
The 75th patient has been enrolled in GENETIC-AF, a phase 2B/3 clinical trial evaluating bucindolol (Gencaro, Arca Biopharma) as a potential treatment for atrial fibrillation.
4WARD Coalition launches website to empower patient/healthcare provider communication
The 4WARD Coalition has launched AFib4WARD.com, an online tool designed to help non-valvular atrial fibrillation patients and their healthcare providers engage in informed discussions and shared decision making.
Intravenous vernakalant superior to ibutilide in recent on-set AF patients
Researchers in Austria have found shorter time to sinus rhythm in patients with recent-onset atrial fibrillation (AF) treated with intravenous vernakalant (Brinavess, Cardiome Pharma) compared with ibutilide treatment.
Arca Biopharma announces update on GENETIC-AF trial
Arca Biopharma has announced the GENETIC-AF trial, which will evaluate bucindolol (Gencaro) as a potential treatment for atrial fibrillation.
Jonathan Kalman
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research groups in the Department of Cardiac Arrhythmias at the Royal Melbourne Hospital and University of Melbourne, Australia. In this interview, he recalls details of the first curative ablation procedure for atrial fibrillation in Australia and talks about the impact of lifestyle modification in atrial fibrillation management.
LuxCath technology demonstrates promising results during first-in-man cardiac ablation procedures
The LuxCath optical tissue interrogation technology was used in eleven patients suffering from arrhythmias such as atrial flutter, AV nodal re-entrant tachycardia, and atrial fibrillation.
The American Heart Association and Heart Rhythm Society coordinate to improve cardiovascular research and...
The American Heart Association (AHA) and Heart Rhythm Society (HRS) have announced a collaboration designed to improve the quality of care of atrial fibrillation (AFib) patients and advance to cardiovascular research.
GARFIELD-AF Registry data to be featured at ESC Congress 2015
A satellite symposium and four GARFIELD-AF presentations will demonstrate how antithrombotic treatment patterns are evolving in the real-world and the impact on clinical outcomes in newly diagnosed atrial fibrillation patients.
ESC announces hot line sessions highlights
Key topics from the hot line sessions of ESC 2015 include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease.
Hansen Medical announces enrolment of initial cohort in ARTISAN US clinical trial
The trial will evaluate the safety and effectiveness of the Sensei robotic system and Artisan family of catheters for introducing and positioning radiofrequency ablation catheters in patients with symptomatic, drug-refractory paroxysmal atrial fibrillation.
Edoxaban approved in the European Union
Edoxaban (Lixiana, Daiichi Sankyo) is an oral, once-daily selective factor Xa-inhibitor for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
AliveCor announces availability of its Mobile ECG in Canada
The AliveCor Mobile ECG and the AliveECG app allows users to detect the presence of atrial fibrillation in an electrocardiogram (ECG or EKG) and manage their heart health with an electrocardiogram ECG monitor.
Medtronic acquires CardioInsight Technologies
CardioInsight Technologies will now become part of the Medtronic Atrial Fibrillation Solutions business in the Cardiac Rhythm and Heart Failure division.
Benefit of anticoagulation in AF patients with a low risk of stroke questioned
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low risk of stroke.
Cryoballoon ablation is not as safe as radiofrequency but is as effective
Armin Luik presented findings at HRS 2015 indicating that cryoballoon ablation is a faster as effective as radiofrequency ablation for pulmonary vein isolation in paroxysmal atrial fibrillation patients, but has a greater complication rate and requires higher X-ray dosages.
Botox reduces AF burden for up to a year after cardiac surgery
Botulinum toxin injected into epicardial fat pads during coronary artery bypass graft surgery reduced the incidence of postoperative atrial fibrillation compared with placebo, with substantial suppression persisting after one year, a pilot study has found.
Edoxaban approved for prevention of stroke and systemic embolism in non-valvular AF and treatment...
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and treatment of venous thromboembolism in deep vein thrombosis.
First patient enrolled in the GOLD AF registry of Medtronic’s PVAC Gold ablation catheter
Medtronic has announced the first patient enrolment in the GOLD AF registry, a first-of-its-kind, prospective, observational clinical study of its Phased Radiofrequency (RF) Ablation technology for treating patients with symptomatic atrial fibrillation.
Long-term sustained weight loss associated with significant reduction in AF burden
The first study investigating the long-term effects of weight loss and the degree of weight fluctuation on atrial fibrillation (AF) burden has found that obese patients with this arrhythmia who lost at least 10% of their body weight were six times more likely to achieve long-term freedom from atrial fibrillation.
Arca biopharma provides GENETIC-AF clinical trial update
The GENETIC-AF phase 2B/3 clinical trial is evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation.
AliveCor launches new app that automatically tells patients when their ECG recording is normal
Anytime an ECG is taken with the AliveCor Heart Monitor, the AliveECG app will tell users if atrial fibrillation is present, if the ECG is normal, or if there is too much interference and another ECG should be taken.
Updated US guidelines suggest an increase by 19% in AF patients recommended for oral...
Two-thirds of patients who were not previously recommended for oral anticoagulation therapy are now recommended, according to an assessment of the 2014 AHA, ACC and HRS atrial fibrillation guidelines.
First patients enrolled in DEEP clinical study
The study is the first-of-its-kind in the USA exploring a minimally invasive epicardial surgical ablation approach combined with an endocardial catheter-based ablation approach for the treatment of persistent or long-standing persistent atrial fibrillation.
Hansen Medical announces expanded protocol for the ARTISAN-AF IDE study
The amended protocol now includes the use of the Thermocool SmartTouch catheter (BioSense Webster) and the EnSite Velocity Cardiac Mapping System (St Jude Medical) in combination with the Sensei Robotic System (Hansen Medical) for the treatment of paroxysmal atrial fibrillation.
Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients
A subanalysis from the ORBIT-AF registry has found that atrial fibrillation patients who receive bridging anticoagulation therapy during anticoagulation interruption are at higher risk of bleeding and adverse events following interruption than patients who do not receive bridging anticoagulation.
Bayer collaborates on phase III study to evaluate Xarelto in embolic stroke patients
In addition, Xarelto (rivaroxaban) label now includes guidance for use in patients with atrial fibrillation undergoing cardioversion.
Guidelines added to ACC Guideline Clinical App
The American College of Cardiology's recently-released Guideline Clinical App has expanded with the addition of tools and guideline content for valvular heart disease and atrial fibrillation.
Long-term overtreatment with antiplatelet/anticoagulant therapy may increase the risk of dementia in AF patients
Atrial fibrillation patients who are receiving a combination of antiplatelet and anticoagulant therapy and are over treated with warfarin may be at an increased risk of dementia, according to a study presented at the American Heart Association's Scientific Sessions (AHA;15-19 November, Chicago, USA).
MiD study unveils key arrhythmia findings in patients with end-stage renal disease
Medtronic has announced the results of a new study which found that atrial fibrillation and bradycardia occurred at higher than expected, and clinically significant, rates in patients with end-stage renal disease undergoing haemodialysis.
Antiarrhythmic drug vernakalant shows positive results in Asia-Pacific phase 3 clinical trial
The study achieved the primary endpoint, showing that 53% of patients with recent onset atrial fibrillation (lasting three hours to seven days) receiving an intravenous dose of vernakalant converted to normal heart rhythm within 90 minutes, compared to 12% of placebo patients.
AtriCure receives FDA approval to start DEEP IDE study
The DEEP study will investigate a minimally invasive approach performed by cardiac surgeons and electrophysiologists to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy.
Rivaroxaban may be a safe alternative to standard of care in AF patients undergoing...
Results from the X-VERT trial have shown that rivaroxaban is a safe and effective alternative to Vitamin K antagonist (VKA) therapy in patients with atrial fibrillation who are undergoing elective cardioversion.
Permanent AF doubles risk of stroke compared to paroxysmal AF
Permanent atrial fibrillation (AF) doubles the risk of stroke compared to paroxysmal AF, according to research in more than 6,000 patients presented at European Society of Cardiology Congress. The findings suggest that a simple clinical assessment of the type of AF can help doctors to better estimate stroke risk.
Favourable effect of Pradaxa on kidney function over time compared to warfarin
New data indicate that kidney function decline is less pronounced in patients with non-valvular atrial fibrillation who are treated with Pradaxa (dabigatran etexilate) compared to warfarin.
SMART-AF trial shows AF ablation with contact force sensing catheter is safe and effective
Results from the SMART-AF trial, recently published in the Journal of the American College of Cardiology, have shown that the ThermoCool SmartTouch contact force-sensing catheter is safe and effective for the treatment of drug-refractory symptomatic paroxysmal atrial fibrillation.
Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary intervention has been published in the European Heart Journal.
AliveCor receives first FDA clearance to detect a serious heart condition in an ECG...
AliveCor has announced that the US Food and Drug Administration (FDA) has granted the company clearance for its algorithm to detect atrial fibrillation.
Study finds Medtronic insertable cardiac monitors detect AF in stroke patients better than standard...
The CRYSTAL AF trial found that continuous cardiac monitoring with the Reveal XT insertable cardiac monitor was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes.
New study of Pradaxa to explore anticoagulation in ablation of AF patients
The RE-CIRCUIT study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa in patients with atrial fibrillation who undergo ablation. Results of the study are expected in 2016.
CRT-D devices with AdaptivCRT associated with reduction of costs of AF
New data from the Medtronic Adaptive CRT trial show a 61% (p=0.01) lower risk of atrial fibrillation (AF)-related problems in patients who receive a cardiac resynchronisation therapy-defibrillator (CRT-D) with the Medtronic-exclusive AdaptivCRT algorithm compared to conventional biventricular pacing therapy.
NICE no longer recommends aspirin alone for reducing risk of stroke in AF patients
Updated National Institute for Health and Care Excellence (NICE) guidelines no longer recommend aspirin use alone, solely to reduce the risk of stroke in patients with atrial fibrillation (AF).
First patient enrolled in Stroke Feasibility Study
The Stroke Feasibility Study is the first US clinical study to evaluate the safety of a novel epicardial-based left atrial appendage closure device for stroke prevention in atrial fibrillation patients.
Cryoballoon faster and more effective than conventional radiofrequency ablation for paroxysmal AF
A randomised controlled trial comparing three methods of pulmonary vein isolation for paroxysmal atrial fibrillation has revealed that procedures were faster and more effective with Medtronic's Arctic Front cryoballoon than wide encirclement using conventional point-by-point radiofrequency ablation. Procedures using the cryoballoon also resulted in a higher single procedure success rate.
Aggressive lifestyle management helps improve success rate after AF ablation
Researchers in Australia have found that aggressive management of cardiovascular risk factors and weight can dramatically impact the long-term success rate of freedom from atrial fibrillation following ablation.